Alex Kwan
Associate Professor in the Meinig School of Biomedical Engineering at Cornell University
Data updated
Research Footprint
Alex Kwan appears in 7 tracked papers (2021–2026), most studied alongside Psilocybin, Ketamine and 5-MeO-DMT, across Depressive Disorders, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: The neural basis of psychedelic action (285 citations).
Frequent co-authors: Clara Liao, Katrin Preller and David Olson.
Background & Research
Alex C. Kwan is an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University. He previously held an associate professorship in the Department of Psychiatry and Department of Neuroscience at Yale School of Medicine, and his training includes engineering physics at Simon Fraser University and applied physics at Cornell University. His research focuses on the neural circuits and structural plasticity underlying rapid-acting antidepressants and psychedelics.
Key Impact
He is a leading psychedelic neuroscience researcher whose work has helped explain how psilocybin and ketamine alter dendritic and circuit-level plasticity linked to antidepressant effects.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Alex Kwan is associated with.
Cornell University
Cornell University is a private Ivy League research university founded in 1865 with its main campus in Ithaca, New York, United States. It has a land-grant mission and operates additional campuses and programs in New York City and abroad.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →